IDIOPATHIC PULMONARY FIBROSIS (IPF)

This study tests whether an oral drug called buloxibutid can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF), a chronic lung-scarring disease. About 378 adults with IPF will receive either buloxibutid or a placebo for 52 weeks. The main goal is to me…

This study tests whether structured exercise programs done at home or via video calls can help people with chronic lung diseases like IPF, sarcoidosis, bronchiectasis, and asthma. About 50 participants will be randomly assigned to home exercise, online group classes, or usual car…

This study tracks 1000 adults with interstitial lung disease to see how often work or home exposures (like chemicals or pollution) play a role. Researchers use a standard questionnaire across multiple centers. The goal is to better understand causes, not to test a new treatment.

This study follows 1,423 adults with idiopathic pulmonary fibrosis (IPF) for up to two years to see how the disease progresses naturally. Researchers will track events like flare-ups, hospital stays, and deaths, and test new ways to measure disease activity. No treatments are giv…

This study follows 250 adults with inherited forms of pulmonary fibrosis to see how their genes influence the speed of lung decline. Participants undergo regular breathing tests and genetic analysis, but no new treatments are tested. The goal is to better understand why some peop…